Supporting Evidence

Imaginot has developed a range of evidence supporting the use of technology to reduce absorption variability, improving drug efficacy and reducing time to peak effect. Evidence includes:

  • In vitro dissolution studies - showing drugs dissolve from SurgeDose® formulations extremely quickly – across a range of media (pH) and stirring conditions simulating in vivo conditions. Click here for more info
  • Phase I / Human pharmacokinetic studies - showing SurgeDose® formulations are absorbed much faster and more consistently than standard formulations with mean Tmax of 20-30 minutes. Click here for more info
  • Pharmacokinetic-pharmacodynamic modelling - results for paracetamol / acetaminophen (APAP) showing improved absorption kinetics drives improved efficacy. Click here for more info
  • Scale up and Stability - Imaginot has scale up, manufacturability and stability data on a range of drugs.  SurgeDose®  formulations can be manufactured with standard tableting equipment but controlled low humidity conditions are essential for stability. Packaging requirements are as for “effervescent tablets”, either unit dose packaging in high integrity films or foil or multidose packaging with desiccants. For more information contact Garth MacDonald at Imaginot
  • IP – Imaginot has three patent families in six jurisdictions, Australia, USA, Canada, Japan, India and Europe. These  cover paracetamol and paracetamol combinations, basic and amphoteric drugs, and acidic and unionised drugs. To date all three patents have been granted in Australia, the paracetamol and bases patents in Canada and the paracetamol (acetaminophen, APAP) patent in the USA.
  • Commercialisation – Imaginot has executed a number of commercial deals including with multinational pharmaceutical companies and drug delivery technology companies.
  • Imaginot has a development partnership with Abbott India to utilise the  SurgeDose®  technology for reformulation of a range of drugs for the Indian Market. The first of these SurgeDose® formulations, lornoxicam was launched in India in September 2011.
  • Imaginot has a co-marketing partnership with Piramal Pharma Solutions, a global contract pharma services company. For more information contact Detlef Behrens at Piramal or Garth MacDonald at Imaginot

Quick links